  |
Market Research in the Healthcare Field with Expertise in Medical Imaging and Radioisotopes
Bio-Tech Systems, Inc. - 4167 West Pinecrest Circle - Las Vegas, Nevada 89121 phone: (702) 456-7608 - fax: (702) 456-2189
THE U.S. MARKET FOR MEDICAL IMAGING CONTRAST MEDIA |
|
BIO-TECH SYSTEMS INC. announces the publication of: BIO-TECH Report #260, The Contrast Media Report Includes:
The markets for MR contrast agents are analyzed in detail, considering the impact of MR angiography and prospects for expanded applications in cardiac and vascular imaging. This includes new products in development and opportunities to utilize biomarkers that will identify diseased tissue and allow targeted therapies focused at the disease site. Prospects for ultrasound contrast agents are covered in depth, with growth forecasts based on approval of indications in cardiac perfusion imaging and eventual approval in radiology abdominal ultrasound. Additional prospects include new porous microbubble agents in development for both MR and ultrasound, with targeting capabilities that will allow imaging and delivery of therapeutic drugs as well as lysis of thrombus, blood clots and vulnerable plaque. This has increased confidence in the prospects for targeted imaging and created a stronger link with therapeutic products based on the same targeting principle. It has also stimulated research in imaging modalities to assess effectiveness of therapeutic agents and evaluate patient response to therapy. The report has a strong focus on new products and technology and emerging market opportunities. Many of the new diagnostic agents offer opportunities to reduce or eliminate more invasive studies, while allowing the clinician to make sensitive and specific diagnoses. Market Analysis and Future Prospects for Contrast Media U.S. sales of medical imaging contrast media reached $1.57 billion in 2006 and are expected to rise to $2.94 billion by 2013. Contrast media sales grew 6% in 2006; however, this annual growth rate is expected to increase to 10-11% per year beyond 2008 as new products are introduced. Iodine sales were $1,028 million in 2006 and have been growing recently at 5-6% per year because of increases in CT procedure volume, notwithstanding competitive pricing. This growth rate will increase as prices stabilize and applications grow in volume. Sales of MR contrast media grew to $364 million in 2006, stimulated by increases in the proportion of enhanced studies. In 2006, 45% of MR studies were enhanced and this proportion should increase in the future. Although sales of MR contrast agents have been under competitive pressure, this market is stabilizing. Therefore, future sales growth will be more consistent with increases in procedure volume. Also, the introduction of new products to enhance MR angiography and permit targeted imaging will favorably affect procedure growth. As a result, contrast media sales should grow conservatively to about $500 million by 2013, with prospects for more rapid growth as new products are introduced. Ultrasound contrast media sales have been growing at a compound rate of over 30% per year recently, with sales of $77.1 million in 2006. Both clinicians and sonographers are gaining more confidence in ultrasound contrast images and have implemented protocols that are simpler and more effective than previously. Although the approved indications are still limited, this will certainly be extended to perfusion imaging in the future. There are two new products on the threshold that have completed Phase 3 clinical trials and it is likely that at least one of these will be approved. Based on these prospects, ultrasound contrast media sales should increase to close to $700 million by 2013. It is also likely that some radiology indications will also be approved that will expand the market for these products. This technical influx will help all segments of the contrast media field with the effect that clinicians will have more options as alternatives to higher risk and more costly invasive procedures. This will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field. Please follow one of the links below, or on the left, to find out more information about BIO-TECH Report #260. If you are interested in purchasing BIO-TECH Report #260, please follow this link to our Online Order Form. To download a detailed Table of Contents (TOC) for BIO-TECH Report #260, please click on one of the two links below. The documents are a Microsoft Word 97-2000 file and an Adobe Acrobat 6 PDF file.  Download TOC in MS Word format (120KB) Download TOC in Adobe PDF format (60KB) |
Back to Top| Report Contents | Partial List of Exhibits |
| Report #260 Home Page |
|
Download Report #260 Table of Contents: BTSI260.doc
-OR-
BTSI260.pdf
|
Send
this page to a friend
Breaking Market News | Orders | News Releases | Contact Us
Report #310 | Report #300 | Report #290 | Report #260 | Report #230 | Top